This clinical trial is focused on studying a type of lung cancer known as RET fusion-positive non-small cell lung cancer (NSCLC). The treatment being tested is a medication called selpercatinib, which is a small molecule kinase inhibitor. This medication is taken orally in the form of a hard capsule. The study also involves a comparison with a placebo, which is a substance with no active medication.

The purpose of the study is to evaluate the effectiveness of selpercatinib in patients who have early-stage RET fusion-positive NSCLC and have already undergone surgery or radiation treatment. Participants in the study will be randomly assigned to receive either selpercatinib or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the trial.

Throughout the study, participants will be monitored to assess the progression of their condition and any potential side effects of the treatment. The trial aims to provide valuable information on whether selpercatinib can improve outcomes for patients with this specific type of lung cancer. The study is expected to continue for several years to gather comprehensive data on the treatment’s effectiveness and safety.